References
1. Blay JY, Kang YK, Nishida T, et al. Gastrointestinal stromal tumours.Nat Rev Dis Primers 2021; 7: 22. 20210318. DOI: 10.1038/s41572-021-00254-5.
2. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Lancet 2009; 373: 1097-1104. 20090318. DOI: 10.1016/S0140-6736(09)60500-6.
3. Serrano C and George S. Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade. Clin Cancer Res 2020; 26: 5078-5085. 20200629. DOI: 10.1158/1078-0432.CCR-20-1706.
4. Seesing MFJ, Tielen R, van Hillegersberg R, et al. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. European Journal of Surgical Oncology (EJSO) 2016; 42: 1407-1413. DOI: 10.1016/j.ejso.2016.02.257.
5. Bayraktar UD. Molecular basis and management of gastrointestinal stromal tumors. World Journal of Gastroenterology 2010; 16. DOI: 10.3748/wjg.v16.i22.2726.
6. Burkill GJ, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003; 226: 527-532. DOI: 10.1148/radiol.2262011880.
7. Brudvik KW, Patel SH, Roland CL, et al. Survival After Resection of Gastrointestinal Stromal Tumor and Sarcoma Liver Metastases in 146 Patients. J Gastrointest Surg 2015; 19: 1476-1483. 20150522. DOI: 10.1007/s11605-015-2845-9.
8. Yamashita K, Baba Y, Kurashige J, et al. Co-occurrence of liver metastasis of gastrointestinal stromal tumor and hepatocellular carcinoma: a case report. Surg Case Rep 2016; 2: 86. 20160901. DOI: 10.1186/s40792-016-0212-z.
9. Turley RS, Peng PD, Reddy SK, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Cancer 2012; 118: 3571-3578. 20111115. DOI: 10.1002/cncr.26650.
10. Badalamenti G, Rodolico V, Fulfaro F, et al. Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features. Annals of Oncology 2007; 18: vi136-vi140. DOI: 10.1093/annonc/mdm243.
11. Miettinen M and Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006; 23: 70-83. DOI: 10.1053/j.semdp.2006.09.001.
12. Kim HC, Lee JM, Choi SH, et al. Cystic changes in intraabdominal extrahepatic metastases from gastrointestinal stromal tumors treated with imatinib. Korean J Radiol 2004; 5: 157-163. DOI: 10.3348/kjr.2004.5.3.157.
13. Hong X, Choi H, Loyer EM, et al. Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib. Radiographics 2006; 26: 481-495. DOI: 10.1148/rg.262055097.
14. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology 2022; 76: 681-693. DOI: 10.1016/j.jhep.2021.11.018.
15. Knight B, Tirnitz-Parker JE and Olynyk JK. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. Gastroenterology 2008; 135: 969-979, 979 e961. 20080603. DOI: 10.1053/j.gastro.2008.05.077.
16. Siegel A. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.Gastroenterology 2008; 135: 733-735. 20080808. DOI: 10.1053/j.gastro.2008.07.036.
17. Nazzal M, Sur S, Steele R, et al. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy. Hepatology 2020; 72: 379-388. DOI: 10.1002/hep.31298.
18. Klug LR, Khosroyani HM, Kent JD, et al. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rev Clin Oncol 2022; 19: 328-341. 20220225. DOI: 10.1038/s41571-022-00606-4.
19. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.J Clin Oncol 2007; 25: 1107-1113. DOI: 10.1200/JCO.2006.09.0183.
20. Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013; 24: 1087-1093. 20121121. DOI: 10.1093/annonc/mds587.
21. Szczepaniak K and Nasierowska-Guttmejer A. The occurrence of gastrointestinal stromal tumors with second malignancies - Case series of a single institution experience. Pathol Res Pract 2021; 228: 153662. 20211020. DOI: 10.1016/j.prp.2021.153662.
22. Murphy JD, Ma GL, Baumgartner JM, et al. Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. Cancer 2015; 121: 2960-2967. 20150430. DOI: 10.1002/cncr.29434.
23. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 2010; 21: 2107-2111. 20100326. DOI: 10.1093/annonc/mdq078.